Nitric oxide donor trans‐[RuCl([15]aneN4)NO]2+ as a possible therapeutic approach for Chagas' disease
- 26 April 2010
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 160 (2) , 270-282
- https://doi.org/10.1111/j.1476-5381.2009.00576.x
Abstract
Background and purpose: Benznidazole (Bz) is the therapy currently available for clinical treatment of Chagas' disease. However, many strains of Trypanosoma cruzi parasites are naturally resistant. Nitric oxide (NO) produced by activated macrophages is crucial to the intracellular killing of parasites. Here, we investigate the in vitro and in vivo activities against T. cruzi, of the NO donor, trans-[RuCl([15]aneN(4))NO]2+. Experimental approach: Trans-[RuCl([15]aneN(4))NO]2+ was incubated with a partially drug-resistant T. cruzi Y strain and the anti-proliferative (epimastigote form) and trypanocidal activities (trypomastigote and amastigote) evaluated. Mice were treated during the acute phase of Chagas' disease. The anti-T. cruzi activity was evaluated by parasitaemia, survival rate, cardiac parasitism, myocarditis and the curative rate. Key results: Trans-[RuCl([15]aneN(4))NO]2+ was 10- and 100-fold more active than Bz against amastigotes and trypomastigotes respectively. Further, trans-[RuCl([15]aneN(4))NO]2+ (0.1 mM) induced 100% of trypanocidal activity (trypomastigotes forms) in vitro. Trans-[RuCl([15]aneN(4))NO]2+ induced permanent suppression of parasitaemia and 100% survival in a murine model of acute Chagas' disease. When the drugs were given alone, parasitological cures were confirmed in only 30 and 40% of the animals treated with the NO donor (3.33 mu mol center dot kg-1 center dot day-1) and Bz (385 mu mol center dot kg-1 center dot day-1), respectively, but when given together, 80% of the animals were parasitologically cured. The cured animals showed an absence of myocarditis and a normalisation of cytokine production in the sera. In addition, no in vitro toxicity was observed at the tested doses. Conclusions and implications: These findings indicate that trans-[RuCl([15]aneN(4))NO]2+ is a promising lead compound for the treatment of human Chagas' disease. This article is commented on by Machado et al., pp. 258-259 of this issue. To view this commentary visit http://dx.doi.org/10.1111/j.1476-5381.2010.00662.x and to view a related paper in this issue by Silva et al. visit http://dx.doi.org/10.1111/j.1476-5381.2010.00524.x.Keywords
This publication has 45 references indexed in Scilit:
- Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesionsZeitschrift Fur Parasitenkunde-Parasitology Research, 2008
- In vitroandin vivoantiproliferative and trypanocidal activities of ruthenium NO donorsBritish Journal of Pharmacology, 2007
- Trypanosoma cruzi high infectivity in vitro is related to cardiac lesions during long-term infection in BeagledogsMemórias do Instituto Oswaldo Cruz, 2007
- Chagas disease in bone marrow transplantation: an approach to preemptive therapyBone Marrow Transplantation, 2005
- Efeito protetor do benznidazol contra a reativação parasitária em pacientes cronicamente infectados pelo Trypanosoma cruzi e tratados com corticóide em virtude de afecções associadasRevista da Sociedade Brasileira de Medicina Tropical, 1999
- Estudo comparativo controlado com emprego de benznidazole, nifurtimox e placebo, na forma crônica da doença de Chagas, em uma área de campo com transmissão interrompida. I. Avaliação preliminarRevista da Sociedade Brasileira de Medicina Tropical, 1997
- Central motor conduction in human chronic Chagas' diseaseArquivos de Neuro-Psiquiatria, 1994
- Sensitivity of parasites to free radical damage by antiparasitic drugsChemico-Biological Interactions, 1990
- Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas diseaseTransactions of the Royal Society of Tropical Medicine and Hygiene, 1987
- Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity.The Journal of Experimental Medicine, 1984